Larsson Susanna C, Burgess Stephen, Michaëlsson Karl
Unit of Nutritional Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
MRC Biostatistics Unit, University of Cambridge, United Kingdom3Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
JAMA. 2017 Jul 25;318(4):371-380. doi: 10.1001/jama.2017.8981.
Serum calcium has been associated with cardiovascular disease in observational studies and evidence from randomized clinical trials indicates that calcium supplementation, which raises serum calcium levels, may increase the risk of cardiovascular events, particularly myocardial infarction.
To evaluate the potential causal association between genetic variants related to elevated serum calcium levels and risk of coronary artery disease (CAD) and myocardial infarction using mendelian randomization.
DESIGN, SETTING, AND PARTICIPANTS: The analyses were performed using summary statistics obtained for single-nucleotide polymorphisms (SNPs) identified from a genome-wide association meta-analysis of serum calcium levels (N = up to 61 079 individuals) and from the Coronary Artery Disease Genome-wide Replication and Meta-analysis Plus the Coronary Artery Disease Genetics (CardiogramplusC4D) consortium's 1000 genomes-based genome-wide association meta-analysis (N = up to 184 305 individuals) that included cases (individuals with CAD and myocardial infarction) and noncases, with baseline data collected from 1948 and populations derived from across the globe. The association of each SNP with CAD and myocardial infarction was weighted by its association with serum calcium, and estimates were combined using an inverse-variance weighted meta-analysis.
Genetic risk score based on genetic variants related to elevated serum calcium levels.
Co-primary outcomes were the odds of CAD and myocardial infarction.
Among the mendelian randomized analytic sample of 184 305 individuals (60 801 CAD cases [approximately 70% with myocardial infarction] and 123 504 noncases), the 6 SNPs related to serum calcium levels and without pleiotropic associations with potential confounders were estimated to explain about 0.8% of the variation in serum calcium levels. In the inverse-variance weighted meta-analysis (combining the estimates of the 6 SNPs), the odds ratios per 0.5-mg/dL increase (about 1 SD) in genetically predicted serum calcium levels were 1.25 (95% CI, 1.08-1.45; P = .003) for CAD and 1.24 (95% CI, 1.05-1.46; P = .009) for myocardial infarction.
A genetic predisposition to higher serum calcium levels was associated with increased risk of CAD and myocardial infarction. Whether the risk of CAD associated with lifelong genetic exposure to increased serum calcium levels can be translated to a risk associated with short-term to medium-term calcium supplementation is unknown.
在观察性研究中,血清钙与心血管疾病相关,随机临床试验的证据表明,提高血清钙水平的补钙治疗可能会增加心血管事件的风险,尤其是心肌梗死。
使用孟德尔随机化方法评估与血清钙水平升高相关的基因变异与冠状动脉疾病(CAD)和心肌梗死风险之间的潜在因果关系。
设计、设置和参与者:分析使用了从血清钙水平的全基因组关联荟萃分析(N = 多达61079人)以及冠状动脉疾病全基因组复制与荟萃分析加上冠状动脉疾病遗传学(CardiogramplusC4D)联盟基于1000基因组的全基因组关联荟萃分析(N = 多达184305人)中鉴定出的单核苷酸多态性(SNP)的汇总统计数据,该分析包括病例(患有CAD和心肌梗死的个体)和非病例,基线数据收集于1948年,人群来自全球各地。每个SNP与CAD和心肌梗死的关联通过其与血清钙的关联进行加权,并使用逆方差加权荟萃分析合并估计值。
基于与血清钙水平升高相关的基因变异的遗传风险评分。
共同主要结局是CAD和心肌梗死的比值比。
在184305人的孟德尔随机分析样本中(60801例CAD病例[约70%患有心肌梗死]和123504例非病例),与血清钙水平相关且与潜在混杂因素无多效性关联的6个SNP估计可解释血清钙水平变异的约0.8%。在逆方差加权荟萃分析(合并6个SNP的估计值)中,遗传预测血清钙水平每升高0.5mg/dL(约1个标准差),CAD的比值比为1.25(95%CI,1.08 - 1.45;P = 0.003),心肌梗死的比值比为1.24(95%CI,1.05 - 1.46;P = 0.0